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Brief description 
Effectiveness of sunscreen in reducing UV-induced skin damage has been proven in 
experimental studies but effectiveness in reducing melanoma in humans remains 
inconclusive. This is the first meta-analysis of data from four different study designs, the first 
to stratify hospital- and population-based case-control studies, and the meta-analysis to 
include the most prospective studies (n=5). We found heterogeneous summary estimates for 
the sunscreen-melanoma association from observational studies but a protective effect of 
sunscreen in the only RCT performed.  
 
Abbreviations 
CI confidence interval 
GRADE 
grading of recommendations assessment, 
development and evaluation 
HR hazard ratio 
p p-value 
N Nord 
NOS Newcastle-Ottawa scale 
OR odds ratio 
RCT randomized controlled trial 
RR rate ratio 
SE summary estimate 
SPF sun protection factor 
USA United States of America 
UV ultraviolet 
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Abstract (248 / 250 words)  
Whether sunscreen use affects melanoma risk has been widely studied with contradictory 
results. To answer this question we performed a systematic review of all published studies, 
accounting for sources of heterogeneity and bias. We searched for original articles 
investigating the sunscreen-melanoma association in humans to 28.02.2018. We then used 
random-effects meta-analysis to combine estimates of the association, stratified by study 
design. Stratified meta-analysis and meta-regression were used to identify sources of 
heterogeneity. We included 21‟069 melanoma cases from 28 studies published 1979-2018: 
23 case-control (11 hospital-based, 12 population-based), 1 ecological, 3 cohort and 1 
randomized controlled trial (RCT). There was marked heterogeneity across study designs 
and among case-control studies but adjustment for confounding by sun exposure, sunburns 
and phenotype systematically moved estimates towards decreased melanoma risk amongst 
sunscreen users. Ever- vs. never-use of sunscreen was inversely associated with melanoma 
in hospital-based case-control studies (adjusted odds ratio (OR)=0.57, 95%confidence 
interval (CI) 0.37-0.87, pheterogeneity<0.001), the ecological study (rate ratio=0.48, 95%CI 0.35-
0.66), and the RCT (hazard ratio (HR)=0.49, 95%CI 0.24-1.01). It was not associated in 
population-based case-control studies (OR=1.17, 95%CI 0.90-1.51, pheterogeneity<0.001) and 
was positively associated in the cohort studies (HR=1.27, 95%CI 1.07-1.51, 
pheterogeneity=0.236). The association differed by latitude (pinteraction=0.042), region 
(pinteraction=0.008), adjustment for naevi/freckling (pinteraction=0.035), and proportion of never-
sunscreen-users (pinteraction=0·012). Evidence from observational studies on sunscreen use 
and melanoma risk was weak and heterogeneous, consistent with the challenges of 
controlling for innate confounding by indication. The only RCT showed a protective effect of 
sunscreen.  
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INTRODUCTION 
Cutaneous melanoma is the leading cause of skin cancer death,1 accounting for 1–2% 
of all cancer deaths.2, 3 In 2015, melanoma occurred in 351‟880 people and resulted in 
59‟782 deaths worldwide.4  
The aetiology of cutaneous melanoma (hereafter termed melanoma) is a complex 
interaction of genetic, epigenetic and environmental risk factors.5, 6 Melanoma is mainly 
caused by ultraviolet (UV) radiation exposure in sun-sensitive subjects and it is estimated 
that more than 85% of melanoma cases in Europe are attributed to sun exposure.7-10 
Genomic sequencing confirms that the majority of the mutations in melanomas are caused 
by UV radiation.11, 12 It follows that melanoma is preventable through reduction of UV 
exposure, making primary prevention highly cost-effective.10, 13 Use of sunscreen is generally 
regarded as a major primary prevention measure alongside seeking shade, wearing 
protective clothes, and avoiding sunbeds,14-17 and is a popular method of sun protection.18 
However effectiveness of sunscreen to reduce UV-induced damage to the skin has been 
proven only in experimental studies,19 and evidence of its effectiveness in preventing 
melanoma in humans is inconclusive. Only one randomized controlled trial (RCT) of daily 
sunscreen application to prevent skin cancer has been performed, showing a reduced risk of 
melanoma (hazard ratio=0.50, p-value=0.051) in those randomly assigned to daily compared 
with discretionary sunscreen use.20, 21 The compliance to daily sunscreen application was 
approximately 75%; the majority of participants in the discretionary sunscreen group either 
did not apply sunscreen (38%) or applied at most once or twice a week (35%).21 All other 
studies of sunscreen and melanoma risk have been observational, mainly case-control, 
yielding contradictory results.22-40  
The main problem with investigating this question with observational studies is 
confounding by indication, i.e. sunscreen users tend to be more susceptible to melanoma 
and more exposed to the sun than non-users a priori.41 The contradictory and heterogeneous 
results of previous systematic reviews reflect this problem.42-48 In the current study we aimed 
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to overcome these known limitations by performing in-depth statistical analyses, comparing 
different patterns of sunscreen use and identifying the major sources of heterogeneity. 
Furthermore we wanted to update the field with new evidence.  
Specifically, we aimed to 1) systematically summarize the existing literature on 
sunscreen use and melanoma in humans; 2) investigate the effect of ever- vs. never-use on 
melanoma risk; 3) assess the effect of different levels and patterns of sunscreen use; 4) 
identify sources of bias and between-study heterogeneity; and 5) describe the relationship 
between site of sunscreen application and site of melanoma.  
 
METHODS 
The study protocol of this systematic review (PROSPERO ID: CRD4201706398049) 
was written according to PRISMA-P50, 51 and the reporting in this article follows the PRISMA 
recommendations.52 
Data Sources and Searches 
We searched the electronic databases PubMed (including Medline), Embase and 
Cochrane Database of Systematic Reviews with search terms adapted for each of them 
(Supplemental Appendix I). In addition, we searched the protocol database PROSPERO to 
identify relevant ongoing reviews and screen their reference lists. To ensure literature 
saturation we also screened the reference lists of relevant published reviews.  
Study Selection 
We included all original articles published by 28.02.2018 in peer-reviewed journals 
arising from case-control studies, ecological studies (population-level rather than individual-
level observational studies), cohort studies intervention studies and clinical trials performed 
in humans with melanoma as endpoint and sunscreen use as exposure. We only included 
studies where the exposure clearly preceded the outcome. We had no restrictions regarding 
length of follow-up or language.  
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Studies on childhood melanoma were included in the qualitative synthesis but 
excluded from the meta-analyses because UV exposure does not seem to be a risk factor in 
the aetiology of melanoma occurring before 15 years of age.53   
All records from the literature research were imported into EndNote (Thomson Reuters, 
version X8), de-duplicated and then imported to Microsoft Excel (version 2010) to perform 
the selection process. Study selection was performed by two independent reviewers (CSR 
and JSS) by first screening titles and abstracts, then screening full texts. We calculated the 
proportion of agreement between the two reviewers for each of the two selection processes. 
Discrepancies were solved by discussion between the two reviewers. References were 
excluded based on the hierarchical exclusion criteria displayed in Figure 1.    
Data Extraction and Quality Assessment 
Data were extracted using a data extraction form54 (Supplemental Appendix II) after 
piloting the process with three studies of different design and publication year. Data 
extraction was performed by CSR and the estimates of interest were double-checked by 
MBV. Discrepancies were discussed among a subgroup of the authors until consensus was 
reached. We contacted study authors and requested the estimate of interest if it was not 
reported but the respective analysis was described. If necessary, additional articles from the 
same study were used to complete data extraction.  
For each study we extracted the following estimates regarding the association of 
sunscreen use and melanoma, if reported: a) ever- vs. never-use of sunscreen from 
minimally adjusted model; b) ever- vs. never-use of sunscreen from maximally adjusted 
model; c) three-level estimate of sunscreen use from maximally adjusted models for 
frequency of use, sun protection factor (SPF) used and duration of use (Supplemental 
Table 1). The minimally and maximally adjusted model was the model with no or only basic 
adjustment and the model with most variables included, respectively, in the original study. 
We chose the ever- vs. never-use label because most underlying studies analysed ever- vs. 
never-use or use vs. no use of sunscreen based on their questionnaires. In addition, we 
This article is protected by copyright. All rights reserved
A
cc
ep
te
d 
A
rti
cl
e
extracted bibliographic and demographic information of the studies, assessment of 
sunscreen use, and study quality to identify sources of heterogeneity. Study quality was 
assessed based on the Cochrane Handbook„s tool for assessing risk of bias54 and the 
Newcastle-Ottawa Scale (NOS).55 Level of bias (high, medium, low) was rated by the data 
extractor (CSR) after reading the methods part of the study and blinded towards the study 
results.  
Data Synthesis and Analysis 
All analyses were performed in STATA (StataCorp LP, Release 14.1). In the analysis 
of ever- vs. never-use of sunscreen we used the method of Hamling and colleagues to 
aggregate estimates if more than two categories of sunscreen use were reported.56 For 
example, if a study reported an estimate with three categories of sunscreen use: never, 
sometimes, and often, we aggregated „sometimes‟ and „often‟ into ever-use. This was done 
to make the estimates across studies more comparable. Without this aggregation we would 
end up pooling estimates across studies where some estimates reflected the effect of the 
highest sunscreen category vs. no sunscreen use, while others reflected ever- vs. never use. 
The same method was used to change the reference category, if necessary. To investigate 
three-level, different patterns and high sunscreen use, we extracted all estimates with at 
least three categories on frequency of sunscreen use, SPF used, and duration of use. For 
each study, the lowest and highest categories were categorized as lowest and highest 
groups, respectively and all intermediate categories were aggregated.57  
We performed random-effects meta-analysis58 stratified by study design for the 
minimally and maximally adjusted estimates of ever- vs. never-use of sunscreen, and for 
each three-level variable on sunscreen use, comparing the intermediate to the lowest level 
and the highest to the lowest level. Heterogeneity between studies was tested with the Q-
test.59 The I2-index was used to quantify the extent of heterogeneity, with I2-values >50%, 
and >75% being indicative of moderate and high heterogeneity, respectively.54 We included 
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one case-cohort study that was analysed together with the cohort studies because it was 
conducted prospectively.  
To explore sources of heterogeneity we performed random-effects meta-analyses 
stratified by important variables predefined in the protocol, and univariable random-effects 
meta-regression analyses, on the maximally adjusted ever- vs. never-use estimate. We 
considered the following variables: study design; year of the end of the data collection (1975-
1984, 1985-1999, 2000-2012); mean latitude (>42°N, ≤42°N);  region; most frequent 
melanoma site in the study population (trunk, head/neck, lower limbs); duration of sunscreen 
use (not specified, specified period, lifetime); level of bias; whether or not the estimate of 
interest was adjusted for nevi and/or freckles, history of sunburn, or sun exposure; and, the 
proportion of participants with blond/red hair (<30%, ≥30%), blue/green eyes (<50%, ≥50%), 
history of sunburn (<75%, ≥75%), and who never used sunscreen (<55%, ≥55%). The cut-
offs in the proportions were chosen based on the distribution of the respective characteristic 
across the studies. We used tau-squared to estimate the remaining between-study variance 
in the meta-regression model by residual maximum likelihood.58 
Publication bias was investigated by the funnel plot and Egger‟s regression test for the 
maximally-adjusted ever-never estimates.60 We used contour-enhanced funnel plots to define 
regions of the plot in which a new study would have to be located to change the statistical 
significance of the meta-analysis and thereby assess the robustness of the current meta-
analysis.61  
Grading of the evidence 
The confidence in the cumulative evidence was assessed using the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) system.62  GRADE 
rates the quality of evidence across the domains risk of bias, consistency, directness, 
precision, and publication bias and rates it into one of the four categories high (further 
research is very unlikely to change our confidence in our effect estimate), moderate (further 
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research is likely to change our confidence in our effect estimate), low (further research is 
very likely to change our effect estimate), or very low (our effect estimate is very uncertain).  
 
RESULTS 
Study selection  
We identified 3414 records in the three databases Pubmed (n=1054), Embase 
(n=2132), and Cochrane (n=228), of which 761 were duplicates and 2552 were rated as 
ineligible on first screening by two reviewers (agreement=95%; Figure 1). Eleven studies 
were identified through other sources resulting in the assessment of 112 full-texts, of which 
84 (agreement=89%) were excluded, leaving 28 studies included in the qualitative synthesis 
and 27 studies in the meta-analysis after exclusion of the childhood melanoma study.32 
Characteristics of included studies 
The 28 articles (11 hospital-based case-control studies,22, 23, 31, 33-35, 37, 39, 63-65 12 
population-based case-control studies,24-30, 32, 36, 38, 40, 66 one ecological study,67 three cohort 
studies (one of them a case-cohort study),68-70 and one RCT21) were published between 1979 
and 2018, included 208 to 178‟155 participants and 33 to 11‟535 melanoma cases: in total, 
21‟069 melanoma cases, who originated from Australia (n=4), Europe (n=16), Brazil (n=2) 
and the USA (n=6; Table 1). The median latitude of the study locations was 43°N (range -
30°S-65°N). On average, 21% of participants (range 9-61%) were blond or red-haired, 47% 
(range 19-86%) blue or green eyed, 48% (range 28-70%) had freckles, and 55% (range 24-
85%) were fair-skinned (Supplemental Table 2). Most studies only assessed sunscreen use 
or sunscreen use frequency (Table 1). Fourteen studies defined a timeframe for the 
sunscreen use,21, 24, 25, 29, 32, 35, 36, 38, 40, 63, 65-68 eight studies assessed the SPF used,21, 35-37, 39, 40, 
66, 69 three the reapplication,40, 65, 66 three the body sites or body coverage,21, 36, 40 two the 
product used,35, 69 two the thickness,21, 40 and one study the reasons for sunscreen use.36 
Methodological quality of included studies 
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The methodological quality of the case-control studies was very heterogeneous with 
11 hospital-based case-control studies based on non-representative cases and controls 
(Supplemental Table 3). The ecological study, cohort studies and RCT fulfilled almost all of 
the methodological requirements.54, 55 
The method and detail of assessment of sunscreen use also varied greatly between 
the studies (Table 2); the same was true for the level of adjustment of the “maximally-
adjusted” estimate, though most studies adjusted in some way for UV exposure and some 
host factors of participants.  
Ever sunscreen use and melanoma risk 
The forest plot of minimally-adjusted estimates showed substantial heterogeneity both 
within hospital-based (I2=86%, p<0.001) and population-based case-control studies (I2=80%, 
p<0.001), and between the different study designs (Figure 2).  
The forest plot of maximally-adjusted estimates showed that adjustment moved most 
estimates towards a more  reduced risk of melanoma amongst sunscreen users (Figures 2 
and 3) though substantial heterogeneity remained (Figure 3), especially within case-control 
studies (I2=86%, p<0.001 for hospital-based; 81%, p<0.001 for population-based) but also 
between study designs. We found an inverse sunscreen-melanoma association in hospital-
based case-control studies (summary odds ratio (OR)=0.57, 95%CI 0.37-0.87), the 
ecological study (rate ratio (RR)=0.48, 95%CI 0.35-0.66), and the RCT (hazard ratio 
(HR)=0.49, 95%CI 0.24-1.01). No association was found on summarizing results from 
population-based case-control studies (OR=1.17, 95%CI 0.90-1.51) and a positive 
sunscreen-melanoma association was seen on summarizing the three cohort studies 
(HR=1.27, 95%CI 1.07-1.51).   
Three-level estimates of sunscreen use and melanoma risk 
Sixteen studies reported at least a three-level estimate on the frequency of sunscreen 
use (never, sometimes, often/always),22, 24-26, 29-31, 33, 35, 36, 38, 40, 63, 68-70 six studies distinguished 
low from high SPF sunscreen use (compared to no use),35-37, 40, 66, 69 and four studies 
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distinguished short-  from long-term use of sunscreen (compared to no use)24, 25, 35, 36 
(Supplemental Table 4). We did not observe a trend or U-shaped association comparing the 
intermediate- and high-users of sunscreen to the non-users for each of the three-level 
estimates (Supplemental Figure 1). The summary estimates comparing sometimes- to 
never-use were 1.07 (95%CI 0.80-1.42) in the hospital-based case-control studies, 1.13 
(95%CI 0.98-1.30) in the population-based case-control studies, and 1.38 (95%CI 1.17-1·62) 
in the cohort studies. The summary estimates comparing often/always- to never-use were 
1.01 (95%CI 0.38-2.67) in the hospital-based case-control studies, 1.01 (95%CI 0.67-1.52) in 
the population-based case-control studies, and 1.32 (95%CI 1.10-1.59) in the cohort studies 
(Supplemental Figure 1A).   
Sources of heterogeneity 
The association between sunscreen use and melanoma from stratified analyses is 
presented in Table 3 and Supplemental Figure 2. Studies conducted in lower latitudes 
showed an inverse association between sunscreen use and melanoma (summary 
estimate=0.64, 95%CI 0.47-0.89 for studies ≤42°N) but there was no association in studies 
from higher latitudes (summary estimate=1.09, 95%CI 0.83-1.44, pinteraction=0·042). Further 
statistically significant interactions were observed between the association of sunscreen use 
and 1) the region of the study (pinteraction=0.008); 2) adjustment for nevi and/or freckles (with 
an inverse association only in studies adjusting; pinteraction=0.035); and, 3) the proportion of 
sunscreen users in the study (with an inverse association of sunscreen use and melanoma 
only in studies where ≥55% of participants never used sunscreen; pinteraction=0.012). 
Remaining between-study variance was generally high after all stratifications (0.047≤tau-
squared≤0.492). 
Site of sunscreen application and site of melanoma  
Two studies21, 36 assessed the body site of sunscreen application but neither related 
this to the site of melanoma. 
Meta bias and quality of the cumulative evidence 
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The funnel plot (Supplemental Figure 3) shows the effect estimates from the 
individual studies against the precision of the studies (standard error in reversed scale), 
placing the largest studies towards the top. In the absence of bias and between-study 
heterogeneity, the plot would have resembled a symmetric inverted funnel, while our plot 
showed evidence of asymmetry confirmed by an Egger‟s test for small-study effects 
(p=0.010). The funnel plot with contours of statistical significance (Supplemental Figure 4) 
shows which combinations of effect size and standard error would be required in an 
additional study, to change or maintain the statistical significance of the current summary 
estimate. In our meta-analysis, the plot showed that all of the current studies were lying in 
the area where future studies (if lying in the same area) would change the current effect 
estimate towards a significantly positive association between sunscreen use and melanoma 
risk (significant effect estimate >1). 
The GRADE assessment resulted in an overall low quality of evidence from the case-
control studies, ecological study and cohort studies, and in a moderate quality of evidence 
from the RCT (Supplemental Table 5).  
 
DISCUSSION 
We assessed the sunscreen-melanoma association in 21‟068 melanoma patients 
based on 28 studies in this comprehensive systematic review. The main body of evidence 
came from observational studies with high between-study heterogeneity. We found an 
inverse association between sunscreen use and melanoma in hospital-based case-control 
studies, the ecological study and the RCT. There was no association in e population-based 
case-control studies and positive association between sunscreen use and melanoma in the 
cohort studies. No clear pattern resulted when comparing the few studies that reported three-
level estimates of sunscreen use regarding frequency of use, SPF of sunscreen used or 
duration of use. The association between sunscreen use and melanoma differed by latitude, 
region, adjustment for nevi/freckling, and proportion of never sunscreen users.  
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Comparison with previous meta-analyses 
This study is the first systematic review and meta-analysis to present results from four 
different study designs, the first to include five prospective studies, and the first to stratify the 
case-control studies into hospital-based and population-based studies. Five meta-analyses 
of the association of sunscreen use and melanoma have been published (in 200243, 200344, 
200745, 201546, and 201848). Only Dennis and colleagues (2003)44 aggregated three-level 
estimates of sunscreen use into ever- vs. never-use, as we did, but  the final estimate 
(pooled OR=1.0, 95%CI 0.8-1.2, from 18 case-control studies) was unadjusted for 
confounding factors. Consistent with our findings, they showed that adjustment moved 
estimates towards a reduced risk of melanoma in sunscreen users, by pooling only the nine 
studies that adjusted for sun sensitivity (OR=0.8, 95%CI 0.6-1.0).44 Similar to our approach, 
Dennis and colleagues tried to go beyond “ever-use” of sunscreen and pooled 12 case-
control studies that reported at least a three-level estimate on the frequency of sunscreen 
use (aggregated by ordered regression models) but found no association.44 
Despite high heterogeneity, the other four meta-analyses pooled results using quite 
different definitions of sunscreen use into one estimate (for example always- vs. never-use 
and ever- vs. never-use), across very different study designs or different types of skin cancer, 
and across estimates from adjusted and unadjusted models. The earliest meta-analysis 
(2002)43 included 11 case-control studies but pooled only the four registry-based, resulting in 
no association (OR=1.01). Gorham and colleagues (2007)45 included 17 case-control studies 
with a pooled OR=1.2 (95%CI 0.9-1.6). Similar to our review, they found statistically 
significant interaction with study latitude. Xie and colleagues (2015)46 included 21 studies and 
calculated a summary estimate of 1.15 (95%CI 0.91-1.44; I2=84%, pheterogeneity<0.001). This 
review46 also tried to identify sources of heterogeneity by meta-regression but found no 
significant interactions. The most recent meta-analysis (2018)48 included 30 studies but only 
25 were related to melanoma. They included only two prospective studies compared to five 
in our review, included cross-sectional study designs and calculated a summary estimate 
This article is protected by copyright. All rights reserved
A
cc
ep
te
d 
A
rti
cl
e
despite high heterogeneity (summary estimate=1.08, 95%CI 0.91-1.29, including melanoma 
and other skin cancers). It is not possible to directly compare the aggregated estimates of 
association from these previous meta-analyses with our sorted and stratified estimates. 
Interpretation of results  
When interpreting our results, we needed to account for the different levels of 
evidence of the study designs included in our meta-analyses. In the hierarchy of strength of 
evidence, ecological studies are the  weakest, and cohort studies and RCTs are the 
strongest.71 Our Funnel plot showed small-study effects, meaning that the results in small 
studies differed from the results in large studies. We suspect that this Funnel plot asymmetry 
is due to poor methodological quality in small studies rather than publication bias.60 This 
supports the fact that our results need to be interpreted taking the methodological quality and 
level of evidence into account as was done in the GRADE assessment.  
Careful interpretation of the results of the observational studies is essential because of 
their multiple methodological limitations when assessing the sunscreen-melanoma 
association: recall bias (in the case-control studies); ecological fallacy (in the ecological study, 
where we do not know whether the specific individuals who used sunscreen were those with 
lower incidence of melanoma because the association was measured at the population level); 
difficulty in meaningfully assessing sunscreen use by ad hoc questionnaires; and, by far the 
most concerning, residual confounding since the determinants of sunscreen use and 
melanoma (susceptibility to sunburn and high sun exposure) are almost inseparable in 
observational studies.41 Furthermore, in their large population-based cohort study,69 
Ghiasvand and colleagues found significant differences between sunscreen users and non-
users in regard to phenotype and sun exposure. Our review highlights the profound influence 
of residual confounding by showing that increasing adjustment systematically moved effect 
estimates towards a more reduced risk of melanoma among sunscreen users. The problems 
incorporated in observational studies have also led to an overall very low quality of evidence 
in the GRADE rating.72 To overcome this problem we suggest performing cohort studies that 
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also explore reasons for sunscreen use and non-use, and how sunscreen users‟ behaviour 
differs from that of non-users,73 or analysing cohort studies using newer statistical methods 
(for example inverse probability weighting of using sunscreen) that can adjust for 
confounding by indication and mimic an RCT design.74 In observational studies, “treatment 
selection” (sunscreen use in our case) is often influenced by subject characteristics. As a 
result, baseline characteristics of subjects using sunscreen differ systematically from those 
not using sunscreen. A propensity score such as inverse probability weights is the probability 
of using sunscreen conditional on observed baseline characteristics. Applying such weights 
allows one to analyse an observational (nonrandomized) study so that it mimics an RCT by 
balancing the distribution of observed baseline covariates between sunscreen users and 
non-users.75    
The strongest existing evidence comes from the one RCT, as suggested by the 
pyramid of evidence.76 The RCT was performed in an Australian population with high year-
round sun exposure and skin cancer awareness.21, 77 There is therefore a need for additional 
high-quality, large RCTs in countries of higher latitude, but these are highly unlikely to be 
conducted because of ethical constraints (vulnerable study participants cannot be denied 
regular use of sunscreen) and the need to enrol extremely large numbers of  participants in 
order to prospectively assess the rare outcome of melanoma.19 However, future RCTs could 
examine intermediate endpoints (biomarkers, genetic mutations) to improve the evidence-
base for sunscreen use.19   
Because of the imprecise definition of ever- vs. never-use of sunscreen and highly 
variable assessment of sunscreen use across studies, we compared the studies reporting at 
least three-levels and different patterns of sunscreen use. Unfortunately very few studies 
reported such estimates, and therefore we could not provide evidence about what pattern of 
use would be most effective and whether there is a discernible trend with increasing 
frequency of sunscreen use. We generally observed that very few studies assessed 
sunscreen use behaviour in depth such as exploring thickness of sunscreen applied, re-
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application or proportion of body covered with sunscreen. Such information would be crucial 
to assess in future research in relation to melanoma risk since we know that most people do 
not apply sunscreen properly.78, 79   
Of further concern is the high heterogeneity between studies that could not be fully 
explained by the variables we investigated in the meta-regression analysis (see also 
heterogeneity between study participants in Supplemental Table 2). We found a more 
protective effect of sunscreens in lower latitudes and Southern countries. This might be due 
to sun exposure being more homogeneous in these studies (everybody is exposed to some 
degree) and to sunscreen use being regarded as a routine preventive measure rather than 
being regarded as a means to prolong sun exposure by some at higher latitudes.80, 81 It would 
therefore be important do distinguish between studies where sunscreen was used for 
intentional sun exposure and tan acquisition versus for protection from sun damage. This 
was not possible with currently available evidence. Also, people from lower and higher 
latitude might differ in their interpretation of frequencies of sunscreen use. For example 
higher latitude participants might consider “often” using sunscreen means applying on sunny 
days, whereas lower latitude participants may think of “often” using sunscreen as daily 
application.  
We further found an inverse association between sunscreen use and melanoma in 
studies where the estimate was adjusted for number of naevi and/or freckling, while no 
association was found in studies without such adjustment. This might be due to the fact that 
number of naevi/freckling are especially important predictors of melanoma,82 and self-
reported assessment of number of naevi/freckling as confounding factor might be more valid 
than other factors (e.g. sun exposure or sunburns long time ago).83, 84 We found an inverse 
association of sunscreen use and melanoma in studies with a high proportion of never 
sunscreen users. This makes sense because of a better contrast between sunscreen users 
and non-users, revealing the effect of sunscreen in populations where the majority is not 
using it.  
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Strengths and limitations 
This systematic review has several strengths. Compared to previous reviews, it adds 
several new studies and study designs, including three large cohort studies, and performs in-
depth statistical analyses. We have extracted a variety of descriptive variables to identify 
sources of heterogeneity. To make the sunscreen variable as comparable as possible 
between studies, we attempted to aggregate or transform the estimates into ever- vs. never-
use of sunscreen in order to combine the studies, but this inherited the weakness that the 
sunscreen measure was very broad, further obscuring  any true effect of sunscreen.  
Other limitations include the relatively low number of eligible studies, especially 
intervention studies and studies reporting three-level estimates on sunscreen use, the 
difference in study designs, and the between-study heterogeneity. Because of the high 
heterogeneity we could not calculate an overall summary estimate. Due to the limited 
number of studies we could not perform multivariable meta-regression analysis, and were 
forced to collapse the meta-regression and stratified meta-analysis over the different study 
designs. Also, we could not identify enough studies to answer our last research question on 
a possible relationship between body sites of sunscreen application and of melanoma. 
Furthermore, we used the label ever- vs. never-use because never or no use were the terms 
mostly used in the original studies included in the meta-analysis. This might be somewhat 
misleading as the never-users probably include some who used sunscreen rarely.  
Conclusion 
We found overall weak and heterogeneous published evidence for an association 
between sunscreen use and melanoma. Observational studies showed an inverse 
association in hospital-based case-control studies and the ecological study, no association in 
population-based case-control studies and a positive association in the three cohort studies. 
A protective effect of sunscreen was found in the only RCT performed. We therefore 
advocate for studies examining intermediate (biological) endpoints to be used in high-quality 
RCTs. The effectiveness of sunscreen to reduce UV radiation to the skin has been proven 
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after acute exposure in human studies and in experimental studies.19 In our review, this 
translated into a reduced melanoma risk in the long-term for only some studies and we 
attribute this to residual confounding of observational studies and the misuse of sunscreen to 
increase rather than decrease sun exposure in some high latitude populations. Public health 
recommendations should place greater emphasis on the proper use of sunscreen (for sun 
protection vs. to prolong time in the sun) in conjunction with other means of sun protection.  
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FIGURE LEGENDS 
Figure 1: Flow diagram on inclusion of studies 
Figure 1 shows the process of selecting eligible studies for the current review and meta-
analysis.  
 
 
Figure 2: Forest plot for ever- vs. never-use of sunscreen and melanoma risk, 
minimally adjusted estimates stratified by study design 
Figure 2 shows the forest plot for melanoma risk comparing ever- vs. never-use of sunscreen 
for all studies that reported a minimally adjusted estimate, stratified by study design. The 
estimates of the case-control studies are reported in odds ratios with 95% confidence 
intervals (CIs); the estimates of the cohort studies and the RCT as hazard ratios with 95% 
CIs; and, the estimate of the ecological study as rate ratio with 95% CI. Minimal adjustment 
of some estimates (e.g. age and sex) and exact definition of the estimates is described in 
Table 2. 
Abbreviations: CI, confidence interval; ES, effect size; RCT, randomized controlled trial. 
* Not ever- vs. never-use of sunscreen; see Table 2 for the exact definition of the estimate. 
** Case-cohort study.  
 
 
Figure 3: Forest plot for ever- vs. never-use of sunscreen and melanoma risk, 
maximally adjusted estimates stratified by study design 
Figure 3 shows the forest plot for melanoma risk comparing ever- vs. never-use of sunscreen 
for all studies that reported a maximally adjusted estimate, stratified by study design. The 
estimates of the case-control studies are reported as odds ratios with 95% confidence 
intervals (CIs); the estimates of the cohort studies and the RCT as hazard ratios with 95% 
CIs; and, the estimate of the ecological study as rate ratio with 95% CI. Adjustment and 
exact definition of the estimates is described in Table 2. 
Abbreviations: CI, confidence interval; ES, effect size; RCT, randomized controlled trial. 
* Not ever- vs. never-use of sunscreen; see Table 2 for the exact definition of the estimate. 
** Case-cohort study. 
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Table 1: Overview of the studies included (n=28) 
First author               
(year) 
Data 
collection 
Country Matching* 
Total no. of 
participants 
No. of 
cases 
Proportion   
of males (%) 
Age range at 
dx (mean) 
Sunscreen information 
assessed† 
Hospital-based case-control studies       
Klepp (1979)
22 
1974-1975 Norway Unmatched 209 78 61 >20 (nr) 
Questionnaire: sunscreen use 
frequency during solar 
irradiation 
Graham (1985)
23
 1974-1980 USA Unmatched 420 218 100 nr (nr) Interview: sunscreen use 
Ródenas (1996)
31
 1989-1993 Spain Unmatched 243 105 35 20-79 (52) 
Interview: sunscreen use 
frequency 
Wolf (1998)
33
 1993-1994 Austria Unmatched 512 193 42 18-89 (54) 
Questionnaire: sunscreen use 
frequency before formation of 
melanoma 
Espinosa A. (1999)
34
 1990-1994 Spain Individual (age, sex) 351 116 47 21-87 (56) Questionnaire: sunscreen use 
Naldi (2000)
35
 1992-1995 Italy Unmatched 1080 542 42 nr (nr) 
Interview: sunscreen use 
frequency and duration, 
product type used, SPF used 
Bakos (2002)
37
 1995-1998 Brazil 
Individual (age, sex, race, 
region) 
309 103 nr 20-84 (53) 
Questionnaire: sunscreen 
use, SPF used 
Nikolaou (2008)
64
 2000-2004 Greece Individual (age, sex) 400 200 49 19-84 (53) Interview: sunscreen use 
Klug (2010)
39
 1991-1992 USA 
Frequency (age, sex, race, 
study site) 
1662 717 55 20-79 (nr) 
Interview: sunscreen use, 
sunscreen use ≥8 SPF, 
regular use ≥8 SPF 
Luiz (2012)
63
 2004-2008 Brazil Frequency (age, sex) 424 202 50 15-79 (48) 
Interview: sunscreen use 
frequency in childhood, 
lifetime sunscreen use 
frequency 
Vranova (2012)
65
 2010-2011 Czech Republic Frequency (age) 518 216 46 nr (54) 
Questionnaire: sunscreen use 
frequency  in childhood, 
sunscreen use frequency in 
adulthood, number of 
sunscreen applications when 
sunbathing 
Population-based case-control studies       
Holman (1986)
24
 1980-1981 Australia 
Individual (age, sex, 
electoral subdivision) 
1014 507 46 10-79 (nr) 
Interview: sunscreen use 
frequency and duration 
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Østerlind (1988)
25
 1982-1985 Denmark Frequency (age, sex) 1400 474 41 20-79 (52) 
Interview: sunscreen use 
frequency and duration 
Beitner (1990)
26
 1978-1983 Sweden Individual (age, sex) 1028 523 45 nr (nr) 
Questionnaire: sunscreen use 
frequency 
Herzfeld (1993)
27 
1982-1983 USA Unmatched 739 324 100 >18 (nr) 
Interview: sunscreen use 
frequency 
Autier (1995)
28
 <1990 
France, Germany, 
Belgium 
Individual (municipality) 856 418 nr nr (nr) Questionnaire: sunscreen use 
Holly (1955)
29
 nr USA Frequency (age) 1382 452 0 25-59 (42) 
Questionnaire: sunscreen use 
frequency in 5 years 
previously 
Westerdahl (1995)
30
 1988-1990 Sweden Individual (age, sex, parish) 1040 400 49 15-75 (nr) 
Questionnaire: sunscreen use 
frequency when spending 
time in the sun 
Whiteman‡ (1997)
32
 1994 Australia 
Individual (sex, school, 
grade) 
208 52 nr 3-14 (nr) 
Questionnaire: sunscreen use 
frequency at school and on 
holidays in childhood 
Westerdahl (2000)
36
 1995-1997 Sweden Individual (age, sex, parish) 1449 558 50 16-80 (nr) 
Questionnaire: sunscreen use 
frequency, regular use, age at 
first use, SPF used, body 
parts applied, reasons for 
sunscreen use 
Youl$ (2002)
38
 1987-1994 Australia 
Individual (age, sex, 
region) 
406 201 50 15-19 (17) 
Interview: sunscreen use 
frequency at school, at home, 
on holidays for ages 5-10, 10-
15, ≥15 years 
Lazovich (2011)
40
 2004-2009 USA Frequency (age, sex) 2268 1167 40 25-59 (nr) 
Interview: lifetime sunscreen 
use frequency during outdoor 
activities, SPF used, 
thickness applied, amount of 
skin covered, reapplication, 
routine use 
Savoye (2018)
66 
1989-2008 France 
Individual (age, birth 
county, education) 
1219 366 0 nr (57) 
Questionnaire: sunscreen use 
at ages <15, 15-25, >25 
years, SPF used, 
reapplication 
Prospective ecological study       
Kojo (2006)
67
 1920-1985 Finland na 11535 11535 47 nr (nr) Sales of sunscreen 
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preparations 5 and 10 years 
before diagnosis 
Prospective cohort studies       
Cho (2005)
68
 1976-2000 USA na 178155¶ 535¶ 32¶ nr (53) 
Questionnaire: sunscreen use 
frequency at the pool or 
beach as a teenager and in 
the past summer 
Ghiasvand (2016)
69
 1991-2012 Norway na 143844 722 0 42-83 (60) 
Questionnaire: sunscreen use 
in low and high latitudes, SPF 
used, brands of sunscreen 
used 
Stenehjem** (2017)
70 
1999-2012 Norway na 1755 112 100 33-84 (58) 
Questionnaire: present 
sunscreen use frequency 
Randomized controlled trial       
Green (2011)
21
 1992-2006 Australia na 1621 33 44 nr (nr) 
Intervention to daily apply 
sunscreen on head, neck, 
arms and hands, weight of 
returned sunscreen bottles, 
questionnaire on weekly 
sunscreen use frequency 
Abbreviations: dx, diagnosis; na, not applicable; nr, not reported; no., number. 
* Only relevant for case-control studies; variables given as reported in the underlying article. 
† This column gives an overview of the sunscreen information assessed in the study. The detailed descriptions of the sunscreen estimates used 
in the meta-analyses are given in Table 2 and Supplemental Table 4.  
‡ Sunscreen and melanoma in childhood. 
$ Sunscreen and melanoma in adolescence. 
¶ Data received upon author request with some differences to the article cited.  
** Case-cohort study design. 
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Table 2: Description of the two-level estimates extracted for each study (described exactly as reported in the articles) 
First author 
(Publ. year) 
Estimate reported in the 
publication 
Aggregated* two-level 
estimate 
Effect 
measure 
Minimally 
adjusted 
estimate          
(95% CI)  
Adjustment of 
minimally 
adjusted 
estimate† 
Maximally 
adjusted 
estimate            
(95% CI) 
Adjustment of maximally 
adjusted estimate† 
Hospital-based case-control studies      
Klepp  
(1979)
22
  
Use of any kind of sun 
lotion/oil during solar 
irradiation: almost never - 
very rarely - sometimes - 
quite often - always  
Use of any kind of sun 
lotion/oil during solar 
irradiation: almost never - 
ever  
OR 
2.05                  
(1.06-4.03) 
None nr  
Graham 
(1985)
23
 
Use of sun screening  
lotion: no - yes 
Use of sun screening  lotion: 
no - yes 
OR 
2.20                   
(1.20-4.10) 
Age nr  
Ródenas 
(1996)
31
 
Sunscreen use: never - 
sometimes - always 
Sunscreen use: never - ever OR 
0.38                     
(0.20-0.70) 
None 
0.43                  
(0.21-0.90) 
Age, skin colour, skin type, 
recreational sun exposure, 
occupational sun exposure, nevi 
Wolf    
(1998)
33
 
Use of sunscreens: never - 
rarely - often 
Use of sunscreens: never - 
ever  
OR 
1.74                       
(1.18-2.57) 
Age, sex 
2.15                         
(1.37-3.37) 
Age, sex, skin colour, sunbaths, 
sunburns 
Espinosa A. 
(1999)
34
 
Use of sunscreens: no - 
yes 
Use of sunscreens: no - yes OR 
0.38                          
(0.28-0.63)‡ 
None 
0.45                                
(0.33-0.67)‡ 
Skin type, freckles, age 
Naldi    
(2000)
35
 
Sunscreen use: never - 
sometimes - often 
Sunscreen use: never - ever  OR 
1.14                        
(0.89-1.45) 
None 
0.90                       
(0.68-1.18) 
Age, sex, demographic area, 
education, skin colour, eye 
colour, hair colour, freckles, nevi, 
sunburns, tanning pattern, sunny 
holiday weeks per year 
Bakos     
(2002)
37
 
Sunscreen use habit: never 
- SPF <8, SPF 8-15, SPF 
15+  
Sunscreen use habit: never - 
ever (all SPF) 
OR 
0.46                        
(0.29-0.74)‡ 
None 
0.34                        
(0.18-0.63)‡ 
Eye colour, hair colour, photo- 
type, freckles, nevi, dysplastic 
nevi, physical protection, sunburn 
Nikolaou 
(2008)
64
  
Sunscreen use: 
never/rarely - during 
summer/sunny months 
Sunscreen use: never/rarely 
- during summer/sunny 
months 
OR 
0.56           
(0.34-0.90) 
Conditional 
regression 
0.37                        
(0.14-0.98) 
Age, gender, phototype, skin 
colour, outdoor leisure activities, 
weeks/year of sun exposure, 
sunburns <20 years of age, 
common nevi, atypical nevi, 
lentigenes 
Klug      
(2010)
39
  
Sunscreen use: no use - 
ever use 
Sunscreen use: no use - ever 
use 
OR 
1.05                           
(0.82-1.35) 
Matched logistic 
regression 
analysis 
0.90                          
(0.70-1.19) 
Gender, age, study site, race, 
ambient resident UV, hours 
outdoors, tan type, sunburns, 
gender, age group, study site 
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Luiz         
(2012)
63
  
Lifetime sunscreen use: 
never/almost never - 
occasionally - modified - 
often 
Lifetime sunscreen use: 
never/almost never - ever 
OR 
0.53                       
(0.22-1.24) 
Age, sex, 
education 
0.34                       
(0.11-1.01) 
Age, sex, education, ethnicity, 
eye colour, history of pigmented 
lesion removal, sunburns age 5-
19, severe lifetime sunburns 
Vranova 
(2012)
65
  
Use of the sunscreen in the 
adulthood: never - 
occasionally - regularly 
Use of the sunscreen in the 
adulthood: never - ever 
OR 
0.63                       
(0.36-1.12)$ 
None 
0.19                       
(0.09-0.43)$ 
Freckles/nevi, sunburns in 
childhood, sunscreen in 
childhood, sunbathing in 
adulthood, sun exposure, time of 
day of sun exposure, holidays at 
seaside, holidays in mountains, 
solarium use 
Population-based case-control studies      
Holman 
(1986)
24
  
Use of sunscreens: never - 
<10 years - ≥10 years 
Use of sunscreens: never - 
ever 
OR nr  
1.11                         
(0.82-1.49) 
Age, sex, electoral subdivision, 
chronic and acute skin reaction to 
sunlight, hair colour, ethnic origin, 
age at arrival in Australia 
Østerlind 
(1988)
25
  
Use of sunscreens: never - 
<10 years - ≥10 years 
Use of sunscreens: never - 
ever 
OR 
1.23                       
(0.98-1.55)$ 
None nr  
Beitner 
(1990)
26
  
Employment of sun 
protection agents: never - 
rarely - often/very often 
Employment of sun 
protection agents: never - 
ever 
OR nr  
1.59                        
(1.17-2.15)‡ 
Age, sex, hair colour 
Herzfeld 
(1993)
27
  
Using sunscreens: no - yes Using sunscreens: no - yes OR 
0.81                      
(0.58-1.12) 
None nr  
Autier  
(1995)
28
  
Regular sunscreen use: 
never - ever 
Regular sunscreen use: 
never - ever 
OR 
1.59                           
(1.18-2.14) 
Conditional 
regression 
1.50                            
(1.09-2.06) 
Age, sex, hair colour, holiday 
weeks in sunny resorts, 
municipality 
Holly      
(1995)
29
  
Use of sunscreen 5 years 
before diagnosis: never - 
sometimes - almost always  
Use of sunscreen 5 years 
before diagnosis: never - 
ever  
OR 
0.67                          
(0.51-0.87)$ 
None 
0.52                          
(0.37-0.73) 
Sunburns ≤12 years, skin 
reaction to sun, hair colour, nevi, 
complexion, maternal ethnicity, 
history of skin cancer, age 
Westerdahl 
(1995)
30
  
 
Use of sunscreens: never - 
sometimes - almost always 
 
Use of sunscreens: never - 
ever  
 
OR 
 
1.65                          
(1.24-2.20) 
 
Matched analysis 
 
1.47                       
(1.08-2.01) 
 
Sunburns, sunbathing in summer, 
outdoor employment in summer, 
nevi, hair colour, eye colour, 
freckling, age, gender, parish 
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Whiteman¶ 
(1997)
32
  
Sunscreen use at school: 
never/rarely - sometimes - 
often - always 
Sunscreen use at school: 
never/rarely - ever 
OR 
1.73                             
(0.97-3.08) 
Matched analysis 
1.01                        
(0.50-2.05) 
Tanning ability, freckling, nevi, 
sex, school, grade  
Westerdahl 
(2000)
36
  
Use of sunscreens: never - 
sometimes - always initially 
of the year then sometimes 
- always 
Use of sunscreens: never - 
ever  
OR 
1.35                         
(1.08-1.69) 
Conditional 
regression 
1.30                          
(0.90-1.90) 
Hair colour, sunburns, sunbathing 
in summer, duration of 
sunbathing, age, sex, parish 
Youl**     
(2002)
38
  
Average lifetime index of 
sunscreen use at home: 
never/rarely - sometimes - 
often/always 
Average lifetime index of 
sunscreen use at home: 
never/rarely – ever 
OR 
1.05                         
(0.63-1.74) 
Conditional 
regression 
nr  
Lazovich 
(2011)
40
 
Routine sunscreen use: 
nonusers in both decades - 
middle - high in both 
decades 
Routine sunscreen use: 
nonusers in both decades - 
users in both decades 
OR 
1.33                         
(0.91-1.95) 
Age, gender 
1.12                             
(0.78-1.62) 
Age, gender, phenotype risk 
score, moles, income, education, 
family history, sunburns, sun 
exposure, solarium use 
Savoye 
(2018)
66
 
Sunscreen use since age 
25: no protection - SPF <8 - 
SPF 8-15 - SPF >15 
Sunscreen use since age 25: 
no protection - SPF <8/SPF 
8-15/SPF >15 
OR 
1.71            
(1.29-2.27) 
Conditional 
regression 
1.50                        
(1.10-2.06) 
Skin sensitivity, nevi, freckling, 
eye colour, skin colour, hair 
colour, hours of recreational sun 
exposure, recreational UV score, 
sunburns >25 years, age, birth 
county, education 
Prospective ecological study      
Kojo          
(2006)
67
 
Rate ratio for CM per 1 
euro increase per capita in 
sunscreen sales 
Rate ratio per 1 euro 
increase per capita in 
sunscreen sales 
RR nr  
0.48                      
(0.35-0.66) 
Age, gender, 10 year lag time, 
sunny resort holidays, holiday 
duration  
Prospective cohort studies      
Cho††              
(2005)
68
  
Percent of time of 
sunscreen use when 
outside at the pool or beach 
in the past summer: 0 - 25 - 
50 - 75 - 100 
Percent of time sunscreen 
used outside at the pool or 
beach in past summer: 0 - 
≥25 
HR 
1.66                       
(1.41-1.96) 
Age 
1.42                          
(1.21-1.68) 
Age, alcohol consumption, 
sunburns, childhood reaction to 
sun, hair colour, smoking, BMI, 
exercise, UV flux, moles, 
caffeine, family history of CM 
Ghiasvand      
(2016)
69
 
Sunscreen use from time-
dependent analysis: never - 
ever 
Sunscreen use from time-
dependent analysis: never - 
ever 
HR 
1.45                        
(1.11-1.90) 
Age, calendar 
year 
1.13                        
(0.85-1.50) 
Age, calendar year, hair colour, 
freckles, ambient UV, weeks 
sunbathing, sunburns, solarium 
use 
Stenehjem‡‡ 
(2017)
70
 
Present sunscreen use: 
never/rarely - often - almost 
always 
Present sunscreen use: 
never/rarely - often/almost 
always 
HR 
1.11                    
(0.69-1.76) 
Age 
1.10                       
(0.77-1.57) 
Age, benzene exposure, 
education 
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Abbreviations: BMI, body mass index; CI, confidence interval; CM, cutaneous melanoma; HR, hazard ratio; nr, not reported; OR, odds ratio; 
Publ., publication; SPF, sun protection factor; RR, rate ratio; RCT, randomized controlled trial; UV, ultraviolet. 
* If sunscreen exposure was reported in more than two categories they were aggregated into two categories (ever- vs. never-use). 
† As reported by the authors. 
‡ Estimate from individual-matched case-control study that did not take the matching into account in the statistical analysis, or did not report it. 
$ Estimate from frequency-matched case-control study that did not adjust for the matching variables in the statistical analysis, or did not report it. 
¶ Sunscreen and melanoma in childhood. 
** Sunscreen and melanoma in adolescence.  
†† Estimates received upon author request because they were not reported in the cited article. 
‡‡ Case-cohort study design. 
 
Randomized controlled trial      
Green          
(2011)
21
  
Random assignment to 
daily or discretionary 
sunscreen application to 
head and 
arms 
Sunscreen application to 
head and arms: daily - 
discretionary 
HR 
0.50                           
(0.24-1.02) 
 
0.49                        
(0.24-1.02) 
Sex, skin type, nevi, history of 
cancer, sun exposure 
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Table 3: Association between sunscreen use and melanoma from stratified analyses 
  No* Estimate 95% CI p† Τau2‡ 
Study design    0.069 0.221 
 Hospital-based case-control studies 9 0.57 0.37-0.87   
 Population-based case-control studies 8 1.17 0.91-1.51   
 Ecological study 1 0.48 0.35-0.66   
 Cohort studies 3 1.27 1.07-1.51   
 Randomized controlled trial 1 0.49 0.24-1.01   
Year of the end of data collection    0.319$ 0.320 
 1975-1984 2 1.33 0.93-1.89   
 1985-1999 10 0.86 0.61-1.21   
 2000-2012 9 0.82 0.60-1.13   
Mean latitude of the study    0.042 0.248 
 >42° N 11 1.09 0.83-1.44   
 ≤42° N 11 0.64 0.47-0.89   
Region of the study    0.008 0.131 
 Northern Europe 6 1.10 0.78-1.57   
 Northern America 4 0.89 0.59-1.34   
 Eastern Europe 1 0.19 0.09-0.42   
 Western Europe 3 1.61 1.32-1.97   
 Southern Europe 4 0.55 0.33-0.89   
 Southern America 2 0.34 0.20-0.59   
 Australia 2 0.79 0.36-1.74   
Most frequent melanoma site    0.825 0.256 
 Trunk 8 0.72 0.49-1.05   
 Head/neck 3 0.93 0.57-1.54   
 Lower limbs 2 0.74 0.29-1.90   
Duration of sunscreen use    0.482 0.313 
 Nothing specified (general habit) 11 0.94 0.69-1.28   
 Specified period 10 0.81 0.60-1.10   
 Lifetime 1 0.34 0.11-1.03   
More detailed assessment than “sunscreen yes-no”  0.493 0.319 
 No (only sunscreen yes-no) 10 0.93 0.66-1.32   
 Yes (more than sunscreen yes-no) 12 0.80 0.60-1.05   
Level of bias    0.884 0.345 
 High 6 0.76 0.42-1.40   
 Medium 12 0.84 0.64-1.12   
 Low 4 1.02 0.73-1.41   
Adjusted for nevi/freckling  0.035 0.238 
 No 8 1.25 0.99-1.56   
 Yes 14 0.69 0.51-0.92   
Adjusted for history of sunburn  0.587 0.323 
 No 6 0.95 0.63-1.44   
 Yes 16 0.82 0.64-1.05   
Adjusted for sun exposure  0.253 0.295 
 No 6 0.64 0.38-1.09   
 Yes 16 0.95 0.77-1.18   
Proportion with blond/red hair  0.150 0.411 
 <30% 10 0.65 0.44-0.97   
 ≥30% 3 1.24 0.80-1.93   
Proportion with blue/green eyes  0.326 0.492 
 <50% 7 0.57 0.35-0.93   
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 ≥50% 4 0.93 0.48-1.79   
Proportion with history of sunburn  0.406 0.429 
 <75% 6 0.62 0.33-1.15   
 ≥75% 7 0.98 0.72-1.31   
Proportion of never¶ sunscreen user  0.012 0.164 
 <55% 13 1.03 0.83-1.28   
 ≥55% 4 0.42 0.32-0.55   
Abbreviations: CI, confidence interval; No, number; p, p-value.  
* Number of studies in each group.  
† P-value for interaction from univariable meta-regression model. 
‡ Remaining between-study variance estimated by residual maximum likelihood.  
$ P-value for trend. 
¶ A few studies included rare sunscreen users in the “never user” category. See Table 2 for 
the exact definition of the sunscreen variable.  
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Effectiveness of sunscreen in reducing UV-induced skin damage has been proven in 
experimental studies, but effectiveness in reducing melanoma in humans remains 
inconclusive. This is the first meta-analysis to analyze data from four study designs, stratify 
hospital- and population-based case-control studies, and include as many as five prospective 
studies. Evidence from observational studies on the sunscreen-melanoma association was 
heterogeneous, consistent with the  challenges of controlling for innate confounding by 
indication. The only randomized controlled trial showed a protective effect. Public health 
recommendations should place greater emphasis on the proper use of sunscreen in conjunction 
with other means of sun protection. 
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